Empaglifozin has cardioprotective and anti-inflammatory effects during doxorubicin treatment: A preclinical study.

Abstract

e23057Background: Empagliflozin (EMPA), a selective inhibitor of the sodium glucose co-transporter 2 (SGLT2), reduces the risk of hospitalization for heart failure or cardiovascular death in type 2...